# A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

> **NCT03861481** · PHASE2 · COMPLETED · sponsor: **UCB Biopharma S.P.R.L.** · enrollment: 34 (actual)

## Conditions studied

- Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

## Interventions

- **DRUG:** Rozanolixizumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03861481
- **Lead sponsor:** UCB Biopharma S.P.R.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-26
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-03-31
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2023-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03861481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03861481, "A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03861481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*